NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/18/2025
Back to search
Official data from USPTO
SSHLNP
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5
Filing date
05/13/2022
Registration date
08/27/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/27/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
MAJCHER HARTNETT, MEGAN K
Law office
N50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
SISAF Ltd
Representatives
Evi T. Christou BANNER & WITCOFF, LTD.
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Nanoparticle substances and nanoparticles for use in industryscience and researchsilicon; silicon for use in industryscience and research; silicon nanoparticle materials for use in industryscience and research; porous silicon nanoparticle materials for use in industryscience and research; lipid nanoparticles for use in industryscience and research; silicon-lipid nanoparticles for use in industryscience and research; silicon-stabilised hybrid lipid nanoparticles for use in industryscience and research; silicon-stabilised lipid nanoparticles for use in industryscience and research; stabilised lipid nanoparticles for use in industryscience and research; chemical materialssilicon for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; chemical materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; chemical materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; chemical materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; chemical materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; chemical materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; chemical materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for stabilising of nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon- stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals
Class 5
Nanoparticle-based pharmaceutical substances and nanoparticle-based pharmaceutical preparations for medicalveterinary and pharmaceutical purposes namely drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccinesporous silicon nanoparticle substances and porous silicon nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; nanoparticle substances and nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposes namelydrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; nanoparticle substances and nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticle substances and lipid nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; drug delivery agentspharmaceutical nanoparticle preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances ; drug delivery agentspharmaceutical silicon nanoparticle preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentspharmaceutical porous silicon nanoparticle preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentslipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentssilicon-lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentssilicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentssilicon-stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentsstabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical nanoparticle preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical silicon nanoparticle preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical porous silicon nanoparticle preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical preparations for stabilising nucleic acids; pharmaceutical nanoparticle preparations for stabilising nucleic acids; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acids; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acids; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid- lipid complexes; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical nanoparticle preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical preparations for controlled release and transfection of nucleic acids; pharmaceutical nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical silicon nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical porous silicon nanoparticle preparations for controlled release and transfection of nucleic acids; lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids
Publications
History of USPTO decisions and trademark events.
32 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/08/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/14/2025
FIMP
FINAL DISPOSITION PROCESSED
02/13/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/27/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/27/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
08/27/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/30/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/11/2024
PUBO
PUBLISHED FOR OPPOSITION
06/11/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/07/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/07/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/22/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/11/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/11/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/27/2023
GNFR
FINAL REFUSAL E-MAILED
11/27/2023
CNFR
FINAL REFUSAL WRITTEN
11/27/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/24/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/24/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/24/2023
RFNT
REFUSAL PROCESSED BY IB
05/17/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/26/2023
RFRR
REFUSAL PROCESSED BY MPU
04/26/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/07/2023
CNRT
NON-FINAL ACTION WRITTEN
03/06/2023
DOCK
ASSIGNED TO EXAMINER
03/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
01/07/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/03/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/30/2022
Continuous trademark protection
Get notified about every new filing that threatens SSHLNP or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.